BioCardia Reports Positive Phase III Echocardiography Results for CardiAMP HF Trial
BCDA sits 37% above its 52-week low of $1.
Summary
BioCardia announced positive echocardiography results from its Phase III CardiAMP HF trial, showing reduced heart remodeling in treated patients, particularly in a key subgroup.
Key Events · Product Development and Regulatory · BCDA
-
Positive Phase III Clinical Trial Results
BioCardia reported late-breaking echocardiography results from its Phase III CardiAMP HF trial for ischemic heart failure, showing reduced negative remodeling of heart volumes in treated patients.
-
Statistically Significant Subgroup Data
A prespecified subgroup of patients with elevated heart stress biomarkers demonstrated clinically meaningful and statistically significant improvements in left ventricular volumes (p=0.02 and p=0.01).
-
Correlation with Primary Endpoints
These echocardiography outcomes correlated with findings for the trial's primary and key secondary endpoints, including reduced major adverse cardiovascular events and improved quality of life.
-
FDA Breakthrough Designation
The CardiAMP Cell Therapy, which is the subject of this trial, has previously been granted FDA Breakthrough designation.
Analysis · BCDA · Life Sciences
This 8-K reports positive late-breaking echocardiography results from BioCardia's Phase III CardiAMP HF clinical trial for ischemic heart failure. The data indicates that treated patients experienced reduced negative remodeling of heart volumes, correlating with improved primary and secondary endpoints. While some results showed trends, a prespecified subgroup with elevated biomarkers achieved statistically significant and clinically meaningful improvements. This positive clinical data is a significant de-risking event for the company's lead product candidate, which holds FDA Breakthrough designation, and could substantially impact its valuation and future prospects.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 36.1% of the 1051 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.56%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BCDA was trading at $1.37 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $14.3M. The 52-week trading range was $1.00 to $3.20. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.